TY - JOUR T1 - Prophylactic antiretroviral HIV therapy prevents infection in heterosexual men and women JF - Evidence Based Medicine JO - Evid Based Med SP - 184 LP - 185 DO - 10.1136/eb-2012-101034 VL - 18 IS - 5 AU - Sarah Fidler AU - Peter Bock Y1 - 2013/10/01 UR - http://ebm.bmj.com/content/18/5/184.abstract N2 - Commentary on: Baeten JM, Donnell D, Ndase P, et al. Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012;367:399–410.OpenUrlCrossRefPubMedWeb of Science Antiretroviral therapy (ART) has dramatically changed both mortality and morbidity associated with HIV infection, but treatment is lifelong and costly. The greatest disease burden, affecting 23 million people, is in Sub Saharan Africa where ART coverage for those in need is estimated at below 60%.1 The continued high rate of new infections demands urgent intervention, and, in the absence of an effective prophylactic vaccine, studies using ART to prevent HIV acquisition among uninfected individuals have been undertaken. Baeten and colleagues report the results of a randomised trial among 4747 HIV-1–serodiscordant heterosexual couples from Kenya and Uganda comparing prophylactic single agent tenofovir (TDF), with tenofovir–emtricitabine (TDF-FTC) against placebo for pre-exposure prophylaxis … ER -